Treatment and Management of Premalignant Breast Lesions
Classification and Risk Assessment
- Nonproliferative lesions, including benign calcifications and fibrocystic changes, carry minimal increased risk 2
Management Algorithm
- Surgical excision is recommended for definitive diagnosis and risk reduction in patients with atypical hyperplasia or LCIS, according to the National Comprehensive Cancer Network (NCCN) 1
- Consider risk-reduction therapy with tamoxifen or other agents according to NCCN Breast Cancer Risk Reduction Guidelines for patients with atypical hyperplasia or LCIS 1
- Regular breast screening with clinical examination 2-3 times per year starting at age 20 is recommended for high-risk women 3
- Mammographic screening starting at age 30 or earlier depending on family history is recommended for high-risk women 3
Risk-Reduction Strategies
- For premenopausal women with confirmed atypical hyperplasia or LCIS, consider tamoxifen (20 mg/day for 5 years) or ovarian function ablation combined with tamoxifen 4
- For postmenopausal women with confirmed atypical hyperplasia or LCIS, consider aromatase inhibitors (anastrozole 1 mg daily or letrozole 2.5 mg daily for 5 years) 4
Follow-up Recommendations
- For lesions determined to be benign after excision, mammography every 6-12 months for 1-2 years before returning to routine screening is recommended 1
- For atypical hyperplasia or LCIS, more intensive surveillance with clinical examination every 3-6 months for 3 years, then every 6-12 months for 3 years, then annually is recommended 4
Important Clinical Considerations
- Geographic correlation between clinical and imaging findings is essential when evaluating suspicious breast lesions 5
- Core needle biopsy is preferred over fine needle aspiration for tissue diagnosis, but surgical excision is often needed for definitive diagnosis of atypical lesions 5, 6